New York, USA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Acinetobacter Infections Clinical Trials Pipeline Analysis: 25+ Companies are Working to Improve the Treatment Space | DelveInsight
Increasing incidence rate of hospital-acquired bacterial infections and the introduction of novel therapeutics that are safe and highly effective are the primary factors that are driving the market growth. This has led several companies to develop innovative therapies for the treatment of Acinetobacter Infections, including Entasis Therapeutics, Qpex Therapeutics, Brii Biosciences, Aridis Pharmaceuticals, VenatoRx Pharmaceuticals, Spero Therapeutics, and several others.
DelveInsight’s 'Acinetobacter Infections Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline Acinetobacter infections therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Acinetobacter infections pipeline domain.
Key Takeaways from the Acinetobacter Infections Pipeline Report
- DelveInsight’s Acinetobacter infections pipeline report depicts a robust space with 25+ active players working to develop 27+ pipeline therapies for Acinetobacter infections treatment.
- Key Acinetobacter infections companies such as Entasis Therapeutics, Spero Therapeutics, Omnix Medical, ABAC Therapeutics, Venatorx Pharmaceuticals, TAXIS Pharmaceutical, Vaxdyn, ContraFect Corporation (CFRX), Debiopharm, Idorsia, Telum Therapeutics, Bioharmony Therapeutics, Destiny Pharma, BioVersys, Hoffmann-La Roche, SuperTrans Medical, Agile Biotics, Qpex Biopharma, Antabio, Nosopharm, Aridis Pharmaceuticals, Brii Biosciences, and others are evaluating novel Acinetobacter infections drug candidates to improve the treatment landscape.
- Promising Acinetobacter infections pipeline therapies in various stages of development include Sulbactam-durlobactam, SPR206, OMN 7, ESKAPE Pathogens bacteriophages, TP-102, VNRX-5113, VXD-001, Debio1454, TP-6076, BH02, XF-73, BV100, AcinetoVax, RG6006, OMNIvance, PBP inhibitors, NOSO-2G, AR-401, BRII-693, and others.
- In December 2022, Brii Biosciences Limited announced progress against its strategic clinical development priorities, including various updates across its pipeline of infectious disease and central nervous system disease candidates. BRII-693 has a highly differentiated safety and efficacy profile to address the most difficult-to-treat Acinetobacter baumannii and Pseudomonas aeruginosa infections resistant to carbapenem. Brii Bio plans to submit a pre-IND to the China NMPA in the first quarter of 2023.
- In November 2022, Innoviva, Inc. announced that the US Food and Drug Administration (FDA) accepted for Priority Review the new drug application (NDA) for SUL-DUR, an investigational drug for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC), including multi-drug resistant and carbapenem-resistant strains. The Agency is currently planning to hold an advisory committee meeting to discuss this application. The target PDUFA date (or action date) is May 29, 2023.
- In June 2022, BioVersys AG, announced that it had raised CHF 24.2 million in the first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. BioVersys intends to complete the Series C investment round by the end of 2022. The company will use the investment to initiate first Phase II clinical trials of BV100 and BVL-GSK098 and the preclinical development of BV200. BV100 addresses serious infections caused by Carbapenem-Resistant Acinetobacter baumannii (CRAB) in hospitalized patients, where mortality currently reaches 50% while BVL-GSK098 targets the 10 million tuberculosis (TB) sufferers identified each year, of which 1.5 million die every year.
- Debiopharm is developing Debio 1454, a FabI inhibitor targeting a combination of enteric bacteria species, A. baumannii, Enterobacter Spp., Klebsiella pneumoniae and E.coli. This compound belongs to a family of narrow-spectrum antiobiotics that combines a very potent activity on pathogens of interest while reducing the selective pressure on other bacterial strains and sparing the microbiome.
Request a sample and discover the recent advances in Acinetobacter infections treatment drugs @ Acinetobacter Infections Pipeline Report
The Acinetobacter infections pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Acinetobacter infections products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Acinetobacter infections pipeline landscape.
Acinetobacter Infections Overview
Acinetobacters are gram-negative aerobic bacilli or coccobacilli in the Moraxellaceae family. They are common and can survive on dry surfaces for up to a month, and they are frequently carried on the skin of healthcare workers, increasing the likelihood of patients being colonized and medical equipment being contaminated. Acinetobacter species are numerous; all can cause human disease, but Acinetobacter baumannii accounts for approximately 80% of infections. Acinetobacter colonizes easily at tracheostomy sites and can cause community-acquired bronchiolitis and tracheobronchitis in healthy children and tracheobronchitis in immunocompromised adults. Acinetobacter pneumonias acquired in hospitals are frequently multilobar and complicated. Secondary bacteremia and septic shock both have poor prognoses.
Infections caused by antibiotic-resistant bacteria Acinetobacter isolates may be treated with broad-spectrum cephalosporins (ceftazidime or cefepime), piperacillin-tazobactam, ampicillin-sulbactam, carbapenems (e.g., meropenem or imipenem-cilastatin), and fluoroquinolones as first-line therapy (e.g., ciprofloxacin). Aminoglycosides and trimethoprim-sulfamethoxazole are also effective first-line treatments for urinary tract infections.
Find out more about therapy for Acinetobacter infections @ Acinetobacter Infections Treatment Drugs
A snapshot of the Acinetobacter Infections Pipeline Drugs mentioned in the report:
|Sulbactam-durlobactam||Entasis Therapeutics||Pre-registration||Beta lactamase inhibitors||Intravenous|
|OMNIvance||Qpex Biopharma||Phase I||Beta lactamase inhibitors||Intravenous|
|XF-73||Destiny Pharma||Preclinical||Cell membrane permeability modulators||NA|
|Debio1454||Debiopharm||Preclinical||Enoyl-ACP reductase inhibitors||Intravenous|
|PBP-539||VenatoRx Pharmaceuticals||Preclinical||Penicillin-binding protein inhibitors||NA|
|SPR 206||Spero Therapeutics||Preclinical||Bacterial outer membrane protein modulators; Cell wall inhibitors||Intravenous|
|Gram negative lysisns||ContraFect Corporatio||Discovery||Cell wall inhibitors||NA|
Learn more about the emerging drugs to treat Acinetobacter infections @ Acinetobacter Infections Clinical Trials
Acinetobacter Infections Therapeutics Assessment
The Acinetobacter infections pipeline report proffers an integral view of the Acinetobacter infections emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Acinetobacter Infections Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravitreal, Subretinal, Topical
- Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Beta lactamase inhibitors, Cell membrane permeability modulators, Enoyl-ACP reductase inhibitors, Penicillin-binding protein inhibitors, Bacterial outer membrane protein modulators; Cell wall inhibitors, Cell wall inhibitors
- Key Acinetobacter Infections Companies: Entasis Therapeutics, Spero Therapeutics, Omnix Medical, ABAC Therapeutics, Venatorx Pharmaceuticals, TAXIS Pharmaceutical, Vaxdyn, ContraFect Corporation (CFRX), Debiopharm, Idorsia, Telum Therapeutics, Bioharmony Therapeutics, Destiny Pharma, BioVersys, Hoffmann-La Roche, SuperTrans Medical, Agile Biotics, Qpex Biopharma, Antabio, Nosopharm, Aridis Pharmaceuticals, Brii Biosciences, and others.
- Key Acinetobacter Infections Pipeline Therapies: Sulbactam-durlobactam, SPR206, OMN 7, ESKAPE Pathogens bacteriophages, TP-102, VNRX-5113, VXD-001, Debio1454, TP-6076, BH02, XF-73, BV100, AcinetoVax, RG6006, OMNIvance, PBP inhibitors, NOSO-2G, AR-401, BRII-693, and others.
Dive deep into rich insights for drugs for Acinetobacter infections treatment; visit @ Acinetobacter Infections Treatment
Table of Contents
|1.||Acinetobacter Infections Pipeline Report Introduction|
|2.||Acinetobacter Infections Pipeline Report Executive Summary|
|3.||Acinetobacter Infections Pipeline: Overview|
|4.||Analytical Perspective In-depth Commercial Assessment|
|5.||Acinetobacter Infections Pipeline Therapeutics|
|6.||Acinetobacter Infections Pipeline: Late Stage Products (Pre-registration)|
|6.1||Sulbactam-durlobactam: Entasis Therapeutics|
|7.||Acinetobacter Infections Pipeline: Late Stage Products (Preregistration)|
|8.||Acinetobacter Infections Pipeline: Mid Stage Products (Phase II)|
|9.||Acinetobacter Infections Pipeline: Early Stage Products (Phase I)|
|9.1||OMNIvance: Qpex Biopharma|
|10.||Acinetobacter Infections Pipeline Therapeutics Assessment|
|11.||Inactive Products in the Acinetobacter Infections Pipeline|
|12.||Company-University Collaborations (Licensing/Partnering) Analysis|
|14.||Key Products in the Acinetobacter Infections Pipeline|
|16.||Market Drivers and Barriers|
|17.||Future Perspectives and Conclusion|
For further information on the Acinetobacter infections pipeline therapeutics, reach out @ Best Therapy for Acinetobacter Infections
Acinetobacter Infections Epidemiology
Acinetobacter Infections Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Acinetobacter infections epidemiology in the 7MM.
Multidrug-Resistant Acinetobacter Infections Market
Multidrug-Resistant Acinetobacter Infections Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted multidrug-resistant Acinetobacter infections epidemiology in the 7MM.
Multidrug-Resistant Acinetobacter Infections Pipeline
Multidrug-Resistant Acinetobacter Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multidrug-resistant Acinetobacter infections companies, including Wockhardt, Tetraphase Pharmaceuticals, Geom Therapeutics, Atterx Biotherapeutics, Hsiri Therapeutics, Antabio, TAXIS Pharmaceutical, Vaxdyn, ContraFect Corporation (CFRX), Debiopharm, among others.
Clostridium difficile Infection Pipeline
Clostridium difficile Infection Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Clostridium difficile infection companies, including Crestone, MicroPharm Ltd., SAb Biotherapeutics, Ferring Pharmaceuticals, Seres Therapeutics, Nestlé Health Science, Finch Therapeutics, among others.
Bacteremia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key bacteremia companies, including Armata Pharmaceuticals, Contrafect, Basilea Pharmaceutical, among others.
Staphylococcus aureus Bacteremia Market
Staphylococcus aureus Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Staphylococcus aureus companies, including ContraFect, XBiotech, Genentech, Durata Therapeutics, among others.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn